Cavu Advisors, LLC sold $200k of ACTU
director, owner at ACTUATE THERAPEUTICS, INC.. 24,999 shares at an average of $8.00, traded Aug 14, 2024, filed Aug 20, 2024.
Score components
- +15RoleDirector
- +12Trade size$200k at market
- 0Share of holdings soldSold 8.2% of holdings
- +15Cluster4 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -3.2%, 3m +5.2%, 6m -10.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-24-091370, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 14, 2024 | SOpen-market sale Common Stockindirect: Directly held by Bios Fund II, LP | -5,314 | $8.00 | $43k | 300,143 | Aug 20, 2024 |
| Aug 14, 2024 | SOpen-market sale Common Stockindirect: Directly held by Bios Fund II QP, LP | -17,361 | $8.00 | $139k | 980,433 | Aug 20, 2024 |
| Aug 14, 2024 | SOpen-market sale Common Stockindirect: Directly held by Bios Fund II NT, LP | -2,324 | $8.00 | $19k | 131,248 | Aug 20, 2024 |
Related signals
Other insiders at ACTUATE THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | ACTUsell ACTUATE THERAPEUTICS, INC. | Todd S Thomson director, owner | $1.6M 280,000 shares | -24% | |
| 58Moderate | ACTUATE THERAPEUTICS, INC. | Aaron G.L. Fletcher director, owner | $500k 71,428 shares | +57% | |
| 58Moderate | ACTUATE THERAPEUTICS, INC. | Leslie W. Kreis director, owner | $500k 71,428 shares | +57% | |
| 58Moderate | ACTUATE THERAPEUTICS, INC. | Bios Equity COF, LP director, owner | $500k 71,428 shares | +57% | |
| 42Moderate | ACTUATE THERAPEUTICS, INC. | Aaron G.L. Fletcher director, owner | $200k 24,999 shares | -8% | |
| 42Moderate | ACTUATE THERAPEUTICS, INC. | Bios Equity COF, LP director, owner | $200k 24,999 shares | -8% | |
| 41Moderate | ACTUATE THERAPEUTICS, INC. | Todd S Thomson director, other | $150k 18,750 shares | -2% | |
| 75Notable | ACTUATE THERAPEUTICS, INC. | Cavu Advisors, LLC director, owner | $4.0M 500,000 shares | +57% | |
| 42Moderate | ACTUATE THERAPEUTICS, INC. | Cavu Advisors, LLC director, owner | $225k 24,999 shares | -8% | |
| 75Notable | ACTUATE THERAPEUTICS, INC. | Aaron G.L. Fletcher director, owner | $4.0M 500,000 shares | +57% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.